Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations.
We examined the influence of both efavirenz plasma concentrations and non-nucleoside reverse transcriptase (NNRTI) resistance mutations on the antiviral activity of efavirenz in patients experiencing early virological failure under nevirapine-containing regimens. Up to 41% of patients reach less than 50 copies/ml at 48 weeks. No association was found between the presence of NNRTI resistance mutations and virological outcome. Nevertheless, patients responding virologically and carrying NNRTI-resistant viruses had higher efavirenz levels than those who did not respond.
González de Requena
Daniel
D
Pharmacology Unit, Hospital Carlos III, Madrid, Spain.
Gallego
Oscar
O
Corral
Angélica
A
Jiménez-Nácher
Inmaculada
I
Soriano
Vincent
V
D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use; D048588:Benzoxazines; D003521:Cyclopropanes; D024882:Drug Resistance, Viral / Q000235:genetics*; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D009154:Mutation / Q000235:genetics*; D019829:Nevirapine / Q000627:therapeutic use; D010078:Oxazines / Q000097:blood / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000097:blood / Q000627:therapeutic use*; D017211:Treatment Failure; D019562:Viral Load
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; C098320:efavirenz